Premium
Ultrasensitive NIR‐SERRS Probes with Multiplexed Ratiometric Quantification for In Vivo Antibody Leads Validation
Author(s) -
Kang Homan,
Jeong Sinyoung,
Jo Ahla,
Chang Hyejin,
Yang JinKyoung,
Jeong Cheolhwan,
Kyeong San,
Lee Youn Woo,
Samanta Animesh,
Maiti Kaustabh Kumar,
Cha Myeong Geun,
Kim TaekKeun,
Lee Sukmook,
Jun BongHyun,
Chang YoungTae,
Chung Junho,
Lee HoYoung,
Jeong Dae Hong,
Lee YoonSik
Publication year - 2018
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201700870
Subject(s) - in vivo , raman scattering , materials science , chemistry , raman spectroscopy , optics , physics , microbiology and biotechnology , biology
Immunotargeting ability of antibodies may show significant difference between in vitro and in vivo. To select antibody leads with high affinity and specificity, it is necessary to perform in vivo validation of antibody candidates following in vitro antibody screening. Herein, a robust in vivo validation of anti‐tetraspanin‐8 antibody candidates against human colon cancer using ratiometric quantification method is reported. The validation is performed on a single mouse and analyzed by multiplexed surface‐enhanced Raman scattering using ultrasensitive and near infrared (NIR)‐active surface‐enhanced resonance Raman scattering nanoprobes (NIR‐SERRS dots). The NIR‐SERRS dots are composed of NIR‐active labels and Au/Ag hollow‐shell assembled silica nanospheres. A 93% of NIR‐SERRS dots is detectable at a single‐particle level and signal intensity is 100‐fold stronger than that from nonresonant molecule‐labeled spherical Au NPs (80 nm). The result of SERRS‐based antibody validation is comparable to that of the conventional method using single‐photon‐emission computed tomography. The NIR‐SERRS‐based strategy is an alternate validation method which provides cost‐effective and accurate multiplexing measurements for antibody‐based drug development.